Why Is CRSP Stock Falling Pre-Market Today?

• CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.
• Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.
• In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.

Structure Of The Convertible Notes

According to the company, the debt securities will rank as senior unsecured obligations. Interest payments will be made twice each year, with the first scheduled payment expected in September 2026. 

Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.

CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs. 

CRISPR Therapeutics stock traded over 6% lower in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours. 

2026 Goals

CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.

In January, it outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.

CRSP stock has gained over 23% in the last 12 months. 

Exchange Rate: 1CHF=1.29USD

Also See: CAPR Stock Surged 17% Today — What’s Fueling The Rally?

For updates and corrections, email newsroom[at]stocktwits[dot]com.